[HTML][HTML] Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis
F Borella, L Bertero, A Morrone, A Gambella, M Bovetti… - Cancers, 2020 - mdpi.com
With this review, we provide the state of the art concerning brain metastases (BMs) from
ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features …
ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features …
[HTML][HTML] Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
X Huang, XY Li, WL Shan, Y Chen, Q Zhu… - Frontiers in …, 2023 - frontiersin.org
Currently, for ovarian cancer, which has the highest mortality rate among all gynecological
cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by …
cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by …
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised …
JA Ledermann, AM Oza, D Lorusso… - The Lancet …, 2020 - thelancet.com
Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-
free survival versus placebo. Here, we report prespecified, investigator-assessed …
free survival versus placebo. Here, we report prespecified, investigator-assessed …
Wet chemical mediated hematite α-Fe2O3 nanoparticles synthesis: preparation, characterization and anticancer activity against human metastatic ovarian cancer
V Ramalingam, M Harshavardhan, SD Kumar - Journal of Alloys and …, 2020 - Elsevier
Ovarian cancer (OC) is the most common gynecologic cancer incidence in female and the
surgery in the major treatment option for OC which makes difficult for survival of OC patients …
surgery in the major treatment option for OC which makes difficult for survival of OC patients …
Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian …
AM Oza, D Lorusso, C Aghajanian, A Oaknin… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To investigate quality-adjusted progression-free survival (QA-PFS) and quality-
adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of …
adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of …
IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway
AH Gao, YR Hu, WP Zhu - Clinical and Translational Oncology, 2022 - Springer
Purpose Ovarian cancer (OC) is a common malignancy, and IFN-γ, a multifunctional
cytokine, is unveiled to impede the multiplication and enhance apoptosis in diverse tumor …
cytokine, is unveiled to impede the multiplication and enhance apoptosis in diverse tumor …
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in …
MP Barretina-Ginesta, BJ Monk, S Han… - Therapeutic …, 2022 - journals.sagepub.com
Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median
progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer …
progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer …
[HTML][HTML] In vitro anticancer activity of ethanol extract of Adhatoda vasica Nees on human ovarian cancer cell lines
JN Nikhitha, KS Swathy, RP Chandran - Journal of Genetic Engineering …, 2021 - Springer
Background Ovarian cancer causes more deaths than any other cancer of the female
reproductive system because there is no effective screening and most women are …
reproductive system because there is no effective screening and most women are …
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized …
AR Clamp, D Lorusso, AM Oza, C Aghajanian… - International Journal of …, 2021 - ijgc.bmj.com
Introduction In ARIEL3 (NCT01968213), the poly (adenosine diphosphate-ribose)
polymerase inhibitor rucaparib significantly improved progression-free survival versus …
polymerase inhibitor rucaparib significantly improved progression-free survival versus …
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
X Wu, J Liu, J Wang, L Wang, Z Lin, X Wang, J Zhu… - Nature Medicine, 2024 - nature.com
Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors as maintenance therapy
after first-line chemotherapy have improved progression-free survival in women with …
after first-line chemotherapy have improved progression-free survival in women with …